Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Income from Continuing Operations came in at 23461000.0 in Q4 2025, up 49.03% YoY from 15742823.2 in Q4 2024, and down 222.27% on a QoQ basis from 7280000.0 in Q3 2025.
Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Income from Continuing Operations data on file, last reported at 23461000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 49.03% year-over-year to 23461000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 87014000.0 (up 146.44% YoY) and the FY2025 annual result came in at 87014000.0, up 146.44% from the prior year.
- Income from Continuing Operations eased to 23461000.0 in Q4 2025, from 7280000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 148451000.0 in Q1 2025 to a low of 91437000.0 in Q2 2023.
- A 5-year average of 25851150.0 and a median of 28492000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 328.21% — and 2025, when it jumped 444.32%.
- Tracing KROS's Income from Continuing Operations over 5 years: stood at 6940000.0 in 2021, then sank by 328.21% to 29718000.0 in 2022, then slumped by 53.36% to 45575000.0 in 2023, then retreated by 0.99% to 46026000.0 in 2024, then soared by 49.03% to 23461000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 23461000.0 (Q4 2025), 7280000.0 (Q3 2025), and 30696000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | -28.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.71 Mn |
| Dec 31, 2025 | -23.46 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -30.70 Mn |
| Mar 31, 2025 | 148.45 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -45.58 Mn |
| Sep 30, 2023 | -76.88 Mn |
| Jun 30, 2023 | -91.44 Mn |
| Mar 31, 2023 | -39.37 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -6.94 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -15.62 Mn |